Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.
Originalsprog | Engelsk |
---|---|
Tidsskrift | PET Clinics |
Vol/bind | 12 |
Udgave nummer | 2 |
Sider (fra-til) | 243-255 |
Antal sider | 13 |
ISSN | 1556-8598 |
DOI | |
Status | Udgivet - apr. 2017 |
ID: 196048622